Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Recommendation of “Moderate Buy” by Brokerages

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has received an average recommendation of “Moderate Buy” from the nineteen ratings firms that are presently covering the firm, Marketbeat reports. Eight research analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $46.71.

APLS has been the subject of several recent research reports. Royal Bank of Canada reissued a “sector perform” rating and set a $26.00 target price on shares of Apellis Pharmaceuticals in a research note on Wednesday, January 29th. Morgan Stanley assumed coverage on Apellis Pharmaceuticals in a report on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 target price on the stock. Bank of America reduced their target price on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Evercore ISI upgraded Apellis Pharmaceuticals to a “strong-buy” rating in a report on Thursday, October 31st. Finally, Piper Sandler decreased their target price on shares of Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating for the company in a report on Wednesday, November 6th.

Insider Activity at Apellis Pharmaceuticals

In other news, CEO Cedric Francois sold 6,247 shares of the stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $28.70, for a total transaction of $179,288.90. Following the transaction, the chief executive officer now owns 307,415 shares of the company’s stock, valued at approximately $8,822,810.50. This represents a 1.99 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO James George Chopas sold 1,096 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total value of $33,351.28. Following the completion of the sale, the chief accounting officer now owns 48,138 shares of the company’s stock, valued at approximately $1,464,839.34. This trade represents a 2.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 60,365 shares of company stock valued at $1,810,479. 6.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Apellis Pharmaceuticals

Several large investors have recently modified their holdings of APLS. KBC Group NV raised its holdings in Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after acquiring an additional 679 shares during the period. Xponance Inc. increased its stake in shares of Apellis Pharmaceuticals by 5.6% in the fourth quarter. Xponance Inc. now owns 14,072 shares of the company’s stock worth $449,000 after purchasing an additional 749 shares during the period. EverSource Wealth Advisors LLC lifted its position in shares of Apellis Pharmaceuticals by 2,707.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock worth $25,000 after purchasing an additional 758 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Apellis Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after purchasing an additional 781 shares during the period. Finally, Signaturefd LLC grew its holdings in Apellis Pharmaceuticals by 357.2% in the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock valued at $37,000 after buying an additional 918 shares during the last quarter. 96.29% of the stock is owned by institutional investors.

Apellis Pharmaceuticals Price Performance

Shares of Apellis Pharmaceuticals stock opened at $27.40 on Friday. Apellis Pharmaceuticals has a 52 week low of $24.34 and a 52 week high of $71.90. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The company’s 50-day moving average price is $31.21 and its two-hundred day moving average price is $32.14. The stock has a market cap of $3.41 billion, a PE ratio of -13.50 and a beta of 0.96.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).